Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Dravet Syndrome, a Rare Form of Epilepsy

2/07/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzqvntavmtivzmlszsjdlfsiccisinrodw1iiiwinjawedqwmfx1mdazzsjdxq

Insys Therapeutics, Inc., a specialty pharmaceutical company that is developing and commercialising innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) for the treatment of Dravet syndrome, a rare pediatric-onset epilepsy.

“There is presently no cure for this catastrophic form of epilepsy, and the significant, unmet need is recognised by the orphan drug designation we received today for our pharmaceutical CBD,” said Michael L. Babich, President and Chief Executive Officer. “Our pharmaceutical CBD is an alternative to plant derived cannabinoids, one which we believe will provide significant medical benefits and better address the unmet needs of patients across multiple indications including Dravet syndrome. We expect to file an Investigational New Drug Application (IND) for CBD in the second half of 2014.”

Insys has more than seven years of research and development experience in the pharmaceutical cannabinoid space. The company manufactures pharmaceutical dronabinol (THC) and pharmaceutical CBD, both of which are cannabinoids, at its FDA-inspected and Drug Enforcement Administration (DEA) approved facility in Round Rock, Texas. Insys believes it is the only U.S.-based company with the capacity to produce pharmaceutical cannabinoids in scalable quantities.

This article has been extracted from http://www.marketwatch.com, please click on this link to read the article in full http://www.marketwatch.com/story/insys-therapeutics-receives-fda-orphan-drug-designation-for-its-pharmaceutical-cannabidiol-as-a-potential-treatment-for-dravet-syndrome-a-rare-form-of-epilepsy-2014-07-02

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdgvmtqvmtmvmjcvmjgvnja2l2nsb3rozxmuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

In Her Shoes... From Market Stall to Recruitment

2017-08-14 14:00:00 +0100

From the melee of the market stall to placing candidates in high-flying IT roles, life's always on the up from market-trader-turned-recruiter, Lois Hinken (22). She took the time to talk to us about how her experience in the cut throat world of the market has helped her in the world of global talent acquisition. As a 360 recruitment consultant for Montash, her negotiation skills and "go get it" attitude have helped her thrive. "I started working on the ...

W1siziisijiwmtcvmdgvmdcvmtmvmtcvntqvnze3l1vudgl0bgvkigrlc2lnbiaomikuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

Will AI Cost Us Our Humanity?

2017-08-07 15:00:00 +0100

As technology evolves, artificial intelligence is becoming increasingly mainstream, and it will inevitably start to impact the way we interact. On the one hand, AI has the potential to solve a variety of problems and streamline our lives and our work. But will this come at the cost of the all-important human touch? A foreshadowing statistic claims that by 2020, 85% of client interactions will be managed without a human[1]. But can there really be an alg...